Want to see IN:BAFNAPH full AI Analyst Report?
Top Page
Bafna Pharmaceuticals Limited
(BAFNAPH)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹319.00
▲(106.27% Upside)
Action:Reiterated
Date:09/08/26
The score is driven most by uneven fundamentals—especially persistently negative free cash flow and margin volatility—partly offset by a strong technical uptrend (price above key moving averages with positive MACD). Valuation is a clear headwind due to the very high P/E and no stated dividend support.
Positive Factors
Multi-year revenue growth
The multi-year expansion indicates that the formulation business has increased its scale and market reach over time. Although recent performance was uneven, a larger revenue base can support operating leverage, broader customer access, and continued sales development over the next several quarters.
Negative Factors
Persistent negative free cash flow
Negative free cash flow in most of the period indicates that reported earnings are not consistently converting into discretionary cash. Persistent cash absorption can reduce financial flexibility, increase reliance on external funding, and constrain the company’s ability to reinvest or withstand operating setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue growth
The multi-year expansion indicates that the formulation business has increased its scale and market reach over time. Although recent performance was uneven, a larger revenue base can support operating leverage, broader customer access, and continued sales development over the next several quarters.
Read all positive factors
Bafna Pharmaceuticals Limited (BAFNAPH) vs. iShares MSCI India ETF (INDA)
Market Cap
₹7.03B
Dividend Yield1.93%
Average Volume (3M)6.84K
Price to Earnings (P/E)91.6
Beta (1Y)0.70
Revenue Growth-3.14%
EPS Growth-5.80%
CountryIN
Employees339
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)3.29
Shares Outstanding23,656,336
10 Day Avg. Volume2,282
30 Day Avg. Volume6,843
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.69
Price to Sales (P/S)1.72
P/FCF Ratio-19.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bafna Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countrie...
How the Company Makes Money
Bafna Pharmaceuticals Limited makes money primarily by selling pharmaceutical formulations (finished dosage products) to customers in its served markets. Key revenue streams typically include (i) sales of branded or generic formulations through do...
Bafna Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
70
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.44B | 1.51B | 1.46B | 1.52B | 1.15B | 851.40M |
| Gross Profit | 329.05M | 201.42M | 168.77M | 452.15M | 387.56M | 338.60M |
| EBITDA | 163.50M | 207.04M | 117.73M | 146.34M | 189.88M | 112.34M |
| Net Income | 77.86M | 111.00M | 41.52M | 73.48M | 113.38M | 52.16M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.76B | 1.53B | 1.48B | 1.30B | 901.45M |
| Cash, Cash Equivalents and Short-Term Investments | 20.25M | 20.25M | 34.33M | 13.96M | 78.09M | 194.00K |
| Total Debt | 0.00 | 374.33M | 281.99M | 243.89M | 229.24M | 110.59M |
| Total Liabilities | -961.50M | 793.83M | 682.73M | 668.43M | 561.29M | 281.81M |
| Stockholders Equity | 961.50M | 961.50M | 848.07M | 808.39M | 734.55M | 619.64M |
Cash Flow | ||||||
| Free Cash Flow | -71.04M | -130.76M | -23.31M | -60.93M | -32.66M | 21.87M |
| Operating Cash Flow | 93.13M | 118.27M | 195.29M | 94.85M | 49.52M | 97.28M |
| Investing Cash Flow | -149.13M | -224.69M | -213.02M | -150.54M | -74.93M | -65.44M |
| Financing Cash Flow | 24.23M | 92.35M | 38.09M | -8.45M | 101.77M | -48.15M |
Bafna Pharmaceuticals Limited Technical Analysis
Positive
154.65
Price Trends
259.86
Positive
207.45
Positive
169.10
Positive
Market Momentum
13.62
Positive
58.67
Neutral
57.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAFNAPH, the sentiment is Positive. The current price of 154.65 is below the 20-day moving average (MA) of 281.52, below the 50-day MA of 259.86, and below the 200-day MA of 169.10, indicating a bullish trend. The MACD of 13.62 indicates Positive momentum. The RSI at 58.67 is Neutral, neither overbought nor oversold. The STOCH value of 57.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BAFNAPH.
Bafna Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹71.55B | 21.90 | ― | 4.00% | -8.88% | -10.68% | |
71 Outperform | ₹73.94B | 36.58 | ― | 0.11% | 28.14% | 11.38% | |
61 Neutral | ₹7.03B | 91.63 | ― | 1.93% | -3.14% | -5.80% | |
58 Neutral | ₹360.70B | 86.62 | ― | 1.27% | 18.37% | ― | |
56 Neutral | ₹28.97B | -82.10 | ― | 0.27% | -5.37% | -153.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₹6.42B | 20.96 | ― | 0.40% | 14.04% | 2.57% |
* General Sector Average
IN:BAFNAPH
Bafna Pharmaceuticals Limited
303.00
184.90
156.56%
IN:HIKAL
Hikal Limited
224.90
-31.93
-12.43%
IN:KILITCH
Kilitch Drugs (India) Limited
186.90
6.72
3.73%
IN:SANOFI
Sanofi India Limited
3,079.85
-1,841.74
-37.42%
IN:SUPRIYA
Supriya Lifescience Limited
903.85
257.12
39.76%
IN:WOCKPHARMA
Wockhardt Limited
2,181.15
663.55
43.72%
Bafna Pharmaceuticals Limited Corporate Events
Bafna Pharmaceuticals Files SEBI Demat Compliance Certificate for June Quarter
Jul 9, 2026
Bafna Pharmaceuticals Limited, a Chennai-based drug maker listed on Indian exchanges, manufactures pharmaceuticals from its facilities in Tamil Nadu and relies on professional registrar and transfer agent services to handle its equity-related comp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.